Generic Name and Formulations:
Tamsulosin HCl 0.4mg; caps.
Boehringer Ingelheim Pharmaceuticals
Indications for FLOMAX:
Swallow whole. Take ½ hr after same meal of each day. Initially 0.4mg once daily; may increase to 0.8mg once daily after 2–4 weeks if response is inadequate. If therapy is interrupted, resume at 0.4mg once daily and retitrate.
Rule out prostate cancer. Sulfa allergy. Syncope. End-stage renal disease. Cataract or glaucoma surgery: do not initiate therapy (possible Intraoperative Floppy Iris Syndrome). Pregnancy (Cat.B).
Do not use with other α-blockers or strong CYP3A4 inhibitors (eg, ketoconazole). Caution with concomitant moderate CYP3A4 inhibitors (eg, erythromycin), moderate or strong CYP2D6 inhibitors (eg, paroxetine, terbinafine), or CYP2D6 poor metabolizers (esp. with tamsulosin >0.4mg/day). Caution with concomitant cimetidine (esp. with tamsulosin >0.4mg/day) or warfarin. Symptomatic hypotension with concomitant PDE5 inhibitors.
Headache, abnormal ejaculation, dizziness, rhinitis, infection, asthenia, back pain, diarrhea, pharyngitis, chest pain, nausea, tooth disorder, blurred vision, cough, somnolence, sinusitis, libido decreased, insomnia; rare: priapism.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma